SITC Resource Library

On July 30, 2018, leading experts in cancer immunotherapy presented an overview of the publication "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of cutaneous melanoma: version 2.0" a during a live webinar. The recorded webinar and presentation slides are available below.

Webinar Faculty:

• Michael B. Atkins, MD - Georgetown-Lombardi Comprehensive Cancer Center
• John M. Kirkwood, MD - UPMC Hillman Cancer Center
• Ryan J. Sullivan, MD - Massachusetts General Hospital

The webinar discussed:

• The role of immunotherapy for the treatment of melanoma
• The role of patient biomarker testing for prognostic use as well as optimizing treatment selection
• Unique disease cases that may require adaption of immunotherapy utilization
• How best to manage immune-related adverse events

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org.

Please note that the on-demand webinar is not available for continuing education credits.

#Biomarkers #Melanoma #PresentationSlides #ClinicalPracticeGuideline #SITC #AdverseEvents #ImmuneCheckpointInhibitors #Ipilimumab#Nivolumab #Pembrolizumab #CombinationTherapy #Clinician #RegisteredNurse #Oncologist #Pharmacist #2018 #RecordedWebinar